Krebs Biochemicals & Industries Limited KREBSBIO NSEPHARMA
Company Overview
Krebs Biochemicals & Industries Limited engages in the manufacture and sale of active pharmaceutical ingredients in India. The company develops biotech processes for application in medicine, agriculture, and industry. Its products include androstenedione, lovastatin, and simvastatin, which are used for anti-cholesterol and steroid intermediate applications. The company also develops various products, including amlodipine, cetirizine, orlistat, serratiopepetidase, telmisartan, and phenylephrine for anti-hypertension, anti-histamine, anti-obesity, anti-inflammatory, and cold and cough applications. In addition, it offers contract manufacturing services for large pharmaceutical and multinational companies. Krebs Biochemicals & Industries Limited was incorporated in 1991 and is based in Visakhapatnam, India.
Why Investors Should Care
Net profit has compounded at 10.5% per year over the last five years.
Recent Developments
- Mar 2026 Revenue of ₹23.73 Cr (-45.2% YoY); net profit ₹-16.93 Cr.
- Trailing 12 Months Year-on-year growth — revenue +11.6%.
- 5-Year Trend Long-term compounding — revenue CAGR -23.1%, profit CAGR 10.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -23.07% |
| 1 Year: | 11.60% |
Compounded Profit Growth
| 5 Years: | 10.47% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -29.72% |
| 6 Months: | -7.99% |
| 3 Months: | -12.71% |
| 1 Month: | -7.47% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)43.94 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Profit CAGR of 10.5% over 5 years.
CONS
- Revenue declined at -23.1% CAGR over 5 years.
- Trading 32.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | KREBSBIO Krebs Biochemicals & Industries Limited NSEPHARMA | 54.12 | -6.89 | ₹116.69 Cr | 0.00% | -19.62% | 10.40% | -23.07% | 10.47% |
| 2 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 8,974.50 | 66.71 | ₹1.29 L Cr | 0.22% | 19.79% | 21.50% | 15.33% | 33.34% |
| 3 | ALKEM Alkem Laboratories Limited NIFTY_MIDNSEPHARMA | 5,597.50 | 29.07 | ₹66,926.51 Cr | 0.35% | 18.56% | 17.56% | 8.30% | 32.74% |
| 4 | ABBOTINDIA Abbott India Limited NIFTY_MIDNSEPHARMA | 27,855.00 | 38.12 | ₹59,189.93 Cr | 1.89% | 41.87% | 34.46% | 9.01% | 17.80% |
| 5 | ANTHEM ANTHEM BIOSCIENCES LTD NIFTY_MIDNSEPHARMA | 825.65 | 81.26 | ₹46,377.90 Cr | 0.24% | 26.77% | 19.45% | 26.20% | 15.39% |
| 6 | AJANTPHARM Ajanta Pharma Limited NIFTY_MIDNSEPHARMA | 3,470.40 | 38.28 | ₹43,357.66 Cr | 1.86% | 29.41% | 23.33% | 13.40% | 21.55% |
| 7 | AGARWALEYE DR AGARWALS HEALTH CARE L NSEPHARMA | 532.30 | 127.96 | ₹16,875.30 Cr | 0.00% | 9.74% | 6.58% | 26.96% | 12.28% |
| 8 | APLLTD Alembic Pharmaceuticals Limited NSEPHARMA | 834.45 | 23.67 | ₹16,402.21 Cr | 1.49% | 12.77% | 12.36% | 9.46% | 25.42% |
| 9 | ALIVUS Alivus Life Sciences Limited NSEPHARMA | 1,325.20 | 27.06 | ₹16,265.43 Cr | 0.38% | 21.78% | 16.94% | 7.61% | 6.53% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 6.10 Cr | 5.48 Cr | 4.17 Cr | 7.27 Cr | 6.81 Cr |
| Cost of Revenue | 56.70 L | 28.92 L | 16,000 | 17,000 | 9.81 L |
| Gross Profit | 5.53 Cr | 5.19 Cr | 4.17 Cr | 7.27 Cr | 6.71 Cr |
| Operating Expenses | 12.51 Cr | 8.88 Cr | 8.58 Cr | 8.61 Cr | 9.14 Cr |
| Operating Income | -6.98 Cr | -3.69 Cr | -4.42 Cr | -1.34 Cr | -2.43 Cr |
| EBITDA | -5.07 Cr | -2.08 Cr | -2.79 Cr | 30.10 L | 1.14 Cr |
| Interest Expense | 1.61 Cr | 1.65 Cr | 1.73 Cr | 1.79 Cr | 1.91 Cr |
| Pretax Income | -8.25 Cr | -5.32 Cr | -6.14 Cr | -3.13 Cr | -2.34 Cr |
| Tax Provision | 1.53 L | 0 | 0 | 0 | 0 |
| Net Income | -8.27 Cr | -5.32 Cr | -6.14 Cr | -3.13 Cr | -2.34 Cr |
| Diluted EPS | -3.83 | -2.47 | -2.85 | -1.45 | -1.09 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 52.13 Cr | 50.42 Cr | 43.31 Cr | 23.73 Cr |
| Cost of Revenue | - | 42.35 Cr | 6.59 Cr | 5.56 Cr | 39.06 L |
| Gross Profit | - | 9.78 Cr | 19.27 Cr | 37.76 Cr | 23.34 Cr |
| Operating Expenses | - | 31.72 Cr | 34.47 Cr | 59.48 Cr | 35.21 Cr |
| Operating Income | - | -21.94 Cr | -15.49 Cr | -21.72 Cr | -11.87 Cr |
| EBITDA | - | -15.16 Cr | -8.28 Cr | -14.32 Cr | -3.42 Cr |
| Interest Expense | - | 2.97 Cr | 4.69 Cr | 5.91 Cr | 7.09 Cr |
| Pretax Income | - | -24.69 Cr | -19.73 Cr | -26.92 Cr | -16.93 Cr |
| Tax Provision | - | 0 | 0 | 1.53 L | 0 |
| Net Income | - | -24.69 Cr | -19.73 Cr | -26.94 Cr | -16.93 Cr |
| Diluted EPS | -20.81 | -11.30 | -9.15 | -12.49 | - |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 174.98 Cr | 178.17 Cr | 169.04 Cr | 163.25 Cr |
| Current Assets | - | 16.06 Cr | 17.44 Cr | 10.26 Cr | 9.62 Cr |
| Cash & Equivalents | - | 1.75 L | 6.91 L | 2.34 L | 12.91 L |
| Inventory | - | 11.95 Cr | 9.80 Cr | 6.03 Cr | 5.70 Cr |
| Receivables | - | 52.52 L | 1.90 Cr | 5.00 L | 43,000 |
| Total Liabilities | - | 274.44 Cr | 297.39 Cr | 315.27 Cr | 326.00 Cr |
| Current Liabilities | - | 49.10 Cr | 61.83 Cr | 103.53 Cr | 113.07 Cr |
| Long Term Debt | - | 173.25 Cr | 183.50 Cr | 161.25 Cr | 163.55 Cr |
| Total Debt | - | 228.37 Cr | 238.68 Cr | 257.21 Cr | 224.84 Cr |
| Total Equity | - | -99.46 Cr | -119.22 Cr | -146.24 Cr | -162.75 Cr |
| Shares Outstanding | - | 2.16 Cr | 2.16 Cr | 2.16 Cr | 2.16 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -24.71 Cr | 2.36 Cr | -7.89 Cr | -1.92 Cr |
| Investing Cash Flow | - | -12.64 Cr | -7.82 Cr | -4.97 Cr | -3.64 Cr |
| Financing Cash Flow | - | 37.34 Cr | 5.50 Cr | 12.86 Cr | 5.54 Cr |
| Capital Expenditure | - | -10.87 Cr | -9.41 Cr | -3.56 Cr | -3.17 Cr |
| Free Cash Flow | - | -35.58 Cr | -7.05 Cr | -11.45 Cr | -5.09 Cr |
| Net Change in Cash | - | -1.49 L | 5.14 L | 42,000 | -1.25 L |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 18.8% | 38.2% | 87.2% | 98.4% |
| Operating Margin % | - | -42.1% | -30.7% | -50.1% | -50.0% |
| Net Margin % | - | -47.4% | -39.1% | -62.2% | -71.4% |
| ROE % | - | 24.8% | 16.5% | 18.4% | 10.4% |
| ROCE % | - | -17.4% | -13.3% | -33.2% | -23.7% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for KREBSBIO
KREBSBIO Stock Price and Chart — NSE:KREBSBIO - TradingView
<a href="https://news.google.com/rss/articles/CBMiXkFVX3lxTE91ZnlTMjFuLXNUa0pnVkdFZDRuNTNQSUI1N3lSZzlRMlEzckI5N2U4UkMzMXE0MEhnNGN4S3h4U2pFMnpBaWw1VnpMMDBUaDVEbWZ6ZHJTc3V4cVlGalE?oc=5" target="_blank">KREBSBIO Stock Price and Chart — NSE:KRE…
PARNAXLAB Stock Price and Chart — BSE:PARNAXLAB - TradingView
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBhQ3BWLWNsekV3T3VGMEswZnc1eEZhQnhRNUs4RWpvSFBzWUNXOE1uNExtaGx2QzlMNDNMWjlyTDJNc1VhaFVoRnM1b1ZxZWxLSTlYTVpDLVJ4YUU1eDZv?oc=5" target="_blank">PARNAXLAB Stock Price and Chart — BSE:P…
B2B jeweller Krizz to raise funds from PE for Rs 800 cr expansion - business-standard.com
<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxPUUt4X1dFdFUyWncyZmVHUE5NalJ6bGR1ZGRlU1RvR1A4aU93OVBnVEVnSlEtSjVGN1NnLXdhMEpWcjVQWF9PSWlNTnA1NzNsNFFpbDZHWENodFNBSDQ2WDk4Vjg5MXA2RjhMT3B6dDV6U3FuLUF6cC1WSll3eE9DTWc3NXBZcnYxbWFEcH…
KIMIABL Stock Price and Chart — BSE:KIMIABL - TradingView
<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTE9zdGpobmROWTJWR1dvOU1kMjV4aVlVYlppajdidWRyQTUtVEtCVTlnVEdnbGZDMXFUN2EwMkxaaHd4SmVjcHFOUnppdm5sanA4Z05zY0U2UkRZV3Zo?oc=5" target="_blank">KIMIABL Stock Price and Chart — BSE:KIMIABL…
KREBSBIO — Frequently Asked Questions
What is the current share price of Krebs Biochemicals & Industries Limited (KREBSBIO)?
As of 2026-08-07 06:31 IST, Krebs Biochemicals & Industries Limited (KREBSBIO) trades at ₹54.12 on NSE. Its 52-week range is ₹39.75 to ₹79.96.
What is the market capitalisation of KREBSBIO?
Krebs Biochemicals & Industries Limited (KREBSBIO) has a market capitalisation of ₹116.69 Cr on NSE.
What is the P/E ratio of KREBSBIO?
KREBSBIO trades at a trailing price-to-earnings (P/E) ratio of -6.89. The industry average P/E is 35.94. Its price-to-book (P/B) ratio is -0.72.
What is the return on equity (ROE) of KREBSBIO?
KREBSBIO has a return on equity (ROE) of 10.40%. Its return on capital employed (ROCE) is -19.62%.
Is KREBSBIO a good stock to buy?
This page provides a data-driven analysis of Krebs Biochemicals & Industries Limited (KREBSBIO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.